Special Webinar - How to Score High and Get Funding
On April 22nd the Virginia Catalyst and Virginia Bio co-hosted a special webinar that featured a panel of experts sharing what it takes to score highly and get funding.
Panel members:
Mike Grisham, President and CEO, Virginia Catalyst, Founder and CEO, GPB Scientific, Inc.
Mickey Kim, former Senior Vice President, Research and Commercialization, Inova Translational Medicine Institute
James Powers, Chairman and CEO, HemoShear Theapeutics, LLC
Thomas D. Roberts III, General Partner, Harbert Growth Partners, Harbert Management Corporation
The recorded webinar can be viewed here on Virginia Bio's website
Click here to view the slides
Read the full press release here
Panel members:
Mike Grisham, President and CEO, Virginia Catalyst, Founder and CEO, GPB Scientific, Inc.
Mickey Kim, former Senior Vice President, Research and Commercialization, Inova Translational Medicine Institute
James Powers, Chairman and CEO, HemoShear Theapeutics, LLC
Thomas D. Roberts III, General Partner, Harbert Growth Partners, Harbert Management Corporation
The recorded webinar can be viewed here on Virginia Bio's website
Click here to view the slides
Read the full press release here
Now Open - Grant Round 11
Emphasis will be placed on Innovative Projects Focused on Solutions for COVID-19 and other Infectious Diseases
Awards range from $200,000 - $800,000
RICHMOND, VA – April 1, 2020 – The Virginia Catalyst, formerly known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 11 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advancing Virginia’s economy.
While all life science projects will be accepted for Grant Round 11, given the impact of COVID-19, emphasis will be placed on projects within the areas of infectious disease, immunology, vaccine and drug discovery, and innovative service delivery models including telehealth and telemedicine.
Read the full press release here
While all life science projects will be accepted for Grant Round 11, given the impact of COVID-19, emphasis will be placed on projects within the areas of infectious disease, immunology, vaccine and drug discovery, and innovative service delivery models including telehealth and telemedicine.
Read the full press release here
Our Strategic Initiatives - Actions and Results for Virginia
At the Virginia Catalyst we specialize in developing and leading strategic initiatives in areas were Virginia can be a national and global leader. We support these initiatives with grant funding for collaborative projects, investments creating research tools, and infrastructure that provide our research universities, healthcare systems and companies a competitive advantage over other regions in the country.
|
Our goal is to have the Commonwealth of Virginia be the very best in the nation at translational medicine and commercialization. We will achieve this by teaming up the biosciences industry with our world-class academic researchers and focusing efforts on solving large unmet medical needs. – Michael Grisham, CEO |
|
Grant Funding Program
Continuing powerful impact through our Grant Funding Program Grant funding for collaborations of universities and industry on commercialization projects Our competitive grant funding rounds, for collaborations of universities and industry on commercialization projects brought Virginia a 10-to-1 return on investment! Our Cumulative Four Year Impact (2014–18) $13.8 million in milestone-based grants awarded to: 27 projects involving 6 universities and 23 companies, Bringing to Virginia: $31.2 million in matching funds from private industry, $137.88 million in follow-on funding, and creating 145 new high paying jobs in Virginia |
Virginia Neuroscience Initiative
Building the infrastructure to support greater success and impact Creating systems and relationships to act as a whole, with a greater potential than any of the parts The Virginia Neuroscience Initiative (VNI) brings together Virginia’s researchers, professors, healthcare providers, university students, and industry partners to create critical mass for scientific, medical and commercial collaborations with a unique and innovate approach. The VNI is home to Neuroscience Interest Groups, each of which members engage in focused webinars, receive announcements of funding opportunities, upcoming events and conferences, and are contacted with opportunities to conduct clinical research studies through our Clinical Trials Network. |
About the Virginia Catalyst
We are a not-for-profit 501(c)(3) corporation created by the Virginia General Assembly and funded by the Commonwealth’s General Fund and seven Virginia public research universities: Eastern Virginia Medical School, George Mason University, Old Dominion University, University of Virginia, Virginia Commonwealth University, Virginia Tech and William & Mary.
Our Mission
Our mission is to advance economic development by creating competitive critical mass for Virginia life sciences through collaborations with our research universities and industry, to attract research and commercialization capital to Virginia and to catalyze the commercialization of Virginia’s innovations that meet large, unmet medical needs, improve human health and to create many more high-paying life science jobs in Virginia.
